CH644456A5 - Method for determination of neuroleptics - Google Patents
Method for determination of neuroleptics Download PDFInfo
- Publication number
- CH644456A5 CH644456A5 CH41778A CH41778A CH644456A5 CH 644456 A5 CH644456 A5 CH 644456A5 CH 41778 A CH41778 A CH 41778A CH 41778 A CH41778 A CH 41778A CH 644456 A5 CH644456 A5 CH 644456A5
- Authority
- CH
- Switzerland
- Prior art keywords
- propyl
- dopamine receptor
- radioactive
- piperidyl
- fluorobenzoyl
- Prior art date
Links
- 238000000034 method Methods 0.000 title claims description 44
- 102000015554 Dopamine receptor Human genes 0.000 claims description 75
- 108050004812 Dopamine receptor Proteins 0.000 claims description 75
- LNEPOXFFQSENCJ-UHFFFAOYSA-N haloperidol Chemical group C1CC(O)(C=2C=CC(Cl)=CC=2)CCN1CCCC(=O)C1=CC=C(F)C=C1 LNEPOXFFQSENCJ-UHFFFAOYSA-N 0.000 claims description 41
- 230000002285 radioactive effect Effects 0.000 claims description 38
- 239000011230 binding agent Substances 0.000 claims description 37
- 239000000463 material Substances 0.000 claims description 36
- VYFYYTLLBUKUHU-UHFFFAOYSA-N dopamine Chemical compound NCCC1=CC=C(O)C(O)=C1 VYFYYTLLBUKUHU-UHFFFAOYSA-N 0.000 claims description 31
- 210000001124 body fluid Anatomy 0.000 claims description 30
- 239000010839 body fluid Substances 0.000 claims description 30
- 239000003176 neuroleptic agent Substances 0.000 claims description 29
- 210000002381 plasma Anatomy 0.000 claims description 28
- 230000000701 neuroleptic effect Effects 0.000 claims description 27
- 210000002966 serum Anatomy 0.000 claims description 27
- 239000003795 chemical substances by application Substances 0.000 claims description 23
- 230000027455 binding Effects 0.000 claims description 21
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 claims description 17
- -1 4-fluorobenzoyl Chemical group 0.000 claims description 16
- 210000001519 tissue Anatomy 0.000 claims description 13
- 239000000203 mixture Substances 0.000 claims description 12
- 230000005764 inhibitory process Effects 0.000 claims description 10
- 125000001255 4-fluorophenyl group Chemical group [H]C1=C([H])C(*)=C([H])C([H])=C1F 0.000 claims description 7
- 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 claims description 7
- 244000309466 calf Species 0.000 claims description 7
- YZCKVEUIGOORGS-NJFSPNSNSA-N Tritium Chemical compound [3H] YZCKVEUIGOORGS-NJFSPNSNSA-N 0.000 claims description 6
- ZPEIMTDSQAKGNT-UHFFFAOYSA-N chlorpromazine Chemical compound C1=C(Cl)C=C2N(CCCN(C)C)C3=CC=CC=C3SC2=C1 ZPEIMTDSQAKGNT-UHFFFAOYSA-N 0.000 claims description 6
- 229910052722 tritium Inorganic materials 0.000 claims description 6
- 239000007853 buffer solution Substances 0.000 claims description 5
- XJGVXQDUIWGIRW-UHFFFAOYSA-N loxapine Chemical compound C1CN(C)CCN1C1=NC2=CC=CC=C2OC2=CC=C(Cl)C=C12 XJGVXQDUIWGIRW-UHFFFAOYSA-N 0.000 claims description 5
- YVUQSNJEYSNKRX-UHFFFAOYSA-N pimozide Chemical compound C1=CC(F)=CC=C1C(C=1C=CC(F)=CC=1)CCCN1CCC(N2C(NC3=CC=CC=C32)=O)CC1 YVUQSNJEYSNKRX-UHFFFAOYSA-N 0.000 claims description 5
- ZEWQUBUPAILYHI-UHFFFAOYSA-N trifluoperazine Chemical compound C1CN(C)CCN1CCCN1C2=CC(C(F)(F)F)=CC=C2SC2=CC=CC=C21 ZEWQUBUPAILYHI-UHFFFAOYSA-N 0.000 claims description 5
- 210000002700 urine Anatomy 0.000 claims description 5
- KLBQZWRITKRQQV-UHFFFAOYSA-N Thioridazine Chemical compound C12=CC(SC)=CC=C2SC2=CC=CC=C2N1CCC1CCCCN1C KLBQZWRITKRQQV-UHFFFAOYSA-N 0.000 claims description 4
- 210000001175 cerebrospinal fluid Anatomy 0.000 claims description 4
- QZUDBNBUXVUHMW-UHFFFAOYSA-N clozapine Chemical compound C1CN(C)CCN1C1=NC2=CC(Cl)=CC=C2NC2=CC=CC=C12 QZUDBNBUXVUHMW-UHFFFAOYSA-N 0.000 claims description 4
- 150000001875 compounds Chemical class 0.000 claims description 4
- 210000005171 mammalian brain Anatomy 0.000 claims description 4
- 125000003854 p-chlorophenyl group Chemical group [H]C1=C([H])C(*)=C([H])C([H])=C1Cl 0.000 claims description 4
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 claims description 4
- RGCVKNLCSQQDEP-UHFFFAOYSA-N Perphenazine Chemical compound C1CN(CCO)CCN1CCCN1C2=CC(Cl)=CC=C2SC2=CC=CC=C21 RGCVKNLCSQQDEP-UHFFFAOYSA-N 0.000 claims description 3
- FFSAXUULYPJSKH-UHFFFAOYSA-N butyrophenone Chemical compound CCCC(=O)C1=CC=CC=C1 FFSAXUULYPJSKH-UHFFFAOYSA-N 0.000 claims description 3
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims description 3
- WJFKNYWRSNBZNX-UHFFFAOYSA-N 10H-phenothiazine Chemical compound C1=CC=C2NC3=CC=CC=C3SC2=C1 WJFKNYWRSNBZNX-UHFFFAOYSA-N 0.000 claims description 2
- FEBOTPHFXYHVPL-UHFFFAOYSA-N 3-[1-[4-(4-fluorophenyl)-4-oxobutyl]-4-piperidinyl]-1H-benzimidazol-2-one Chemical compound C1=CC(F)=CC=C1C(=O)CCCN1CCC(N2C(NC3=CC=CC=C32)=O)CC1 FEBOTPHFXYHVPL-UHFFFAOYSA-N 0.000 claims description 2
- ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical compound [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 claims description 2
- 210000001159 caudate nucleus Anatomy 0.000 claims description 2
- 229910052740 iodine Inorganic materials 0.000 claims description 2
- 239000011630 iodine Substances 0.000 claims description 2
- 229950000688 phenothiazine Drugs 0.000 claims description 2
- 239000012086 standard solution Substances 0.000 claims description 2
- MKJDUHZPLQYUCB-UHFFFAOYSA-N decan-4-one Chemical compound CCCCCCC(=O)CCC MKJDUHZPLQYUCB-UHFFFAOYSA-N 0.000 claims 4
- SILNNFMWIMZVEQ-UHFFFAOYSA-N 1,3-dihydrobenzimidazol-2-one Chemical compound C1=CC=C2NC(O)=NC2=C1 SILNNFMWIMZVEQ-UHFFFAOYSA-N 0.000 claims 2
- NJMYODHXAKYRHW-UHFFFAOYSA-N 2-[4-[3-[2-(trifluoromethyl)-9-thioxanthenylidene]propyl]-1-piperazinyl]ethanol Chemical compound C1CN(CCO)CCN1CCC=C1C2=CC(C(F)(F)F)=CC=C2SC2=CC=CC=C21 NJMYODHXAKYRHW-UHFFFAOYSA-N 0.000 claims 2
- WCSKAACMAHMNMT-UHFFFAOYSA-N 6-methyl-5,6,6a,7-tetrahydro-4H-dibenzo[de,g]quinoline-3,4-diol Chemical compound OC=1C=CC=2C3=CC=CC=C3CC3N(CC(C=1C=23)O)C WCSKAACMAHMNMT-UHFFFAOYSA-N 0.000 claims 2
- WFPIAZLQTJBIFN-UHFFFAOYSA-N clopenthixol Chemical compound C1CN(CCO)CCN1CCC=C1C2=CC(Cl)=CC=C2SC2=CC=CC=C21 WFPIAZLQTJBIFN-UHFFFAOYSA-N 0.000 claims 2
- PFECUZFGOLPJLT-UHFFFAOYSA-N 2-[2-[3-(2-chlorophenothiazin-10-yl)propyl]piperazin-1-yl]ethanol Chemical compound OCCN1CCNCC1CCCN1C2=CC(Cl)=CC=C2SC2=CC=CC=C21 PFECUZFGOLPJLT-UHFFFAOYSA-N 0.000 claims 1
- 125000003236 benzoyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C(*)=O 0.000 claims 1
- NPUACKRELIJTFM-UHFFFAOYSA-N cr gas Chemical compound C1=NC2=CC=CC=C2OC2=CC=CC=C21 NPUACKRELIJTFM-UHFFFAOYSA-N 0.000 claims 1
- 125000002816 methylsulfanyl group Chemical group [H]C([H])([H])S[*] 0.000 claims 1
- FPVZWDQWFCGSFY-UHFFFAOYSA-N spiro[4.5]decan-4-one Chemical compound O=C1CCCC11CCCCC1 FPVZWDQWFCGSFY-UHFFFAOYSA-N 0.000 claims 1
- 229960003878 haloperidol Drugs 0.000 description 28
- 238000012360 testing method Methods 0.000 description 23
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 18
- 239000000872 buffer Substances 0.000 description 16
- 239000003814 drug Substances 0.000 description 15
- 102000005962 receptors Human genes 0.000 description 15
- 108020003175 receptors Proteins 0.000 description 15
- 238000011088 calibration curve Methods 0.000 description 13
- 229940079593 drug Drugs 0.000 description 13
- 239000003446 ligand Substances 0.000 description 13
- QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 12
- 210000004369 blood Anatomy 0.000 description 12
- 239000008280 blood Substances 0.000 description 12
- 229960003638 dopamine Drugs 0.000 description 12
- BTCSSZJGUNDROE-UHFFFAOYSA-N gamma-aminobutyric acid Chemical compound NCCCC(O)=O BTCSSZJGUNDROE-UHFFFAOYSA-N 0.000 description 10
- 229960005070 ascorbic acid Drugs 0.000 description 9
- 235000010323 ascorbic acid Nutrition 0.000 description 9
- 239000011668 ascorbic acid Substances 0.000 description 9
- 230000000694 effects Effects 0.000 description 9
- 229960003692 gamma aminobutyric acid Drugs 0.000 description 9
- IMNFDUFMRHMDMM-UHFFFAOYSA-N N-Heptane Chemical compound CCCCCCC IMNFDUFMRHMDMM-UHFFFAOYSA-N 0.000 description 8
- 238000010790 dilution Methods 0.000 description 8
- 239000012895 dilution Substances 0.000 description 8
- 238000011534 incubation Methods 0.000 description 8
- 239000007788 liquid Substances 0.000 description 8
- 241000700159 Rattus Species 0.000 description 6
- 210000004556 brain Anatomy 0.000 description 6
- 238000000605 extraction Methods 0.000 description 6
- PHTQWCKDNZKARW-UHFFFAOYSA-N isoamylol Chemical compound CC(C)CCO PHTQWCKDNZKARW-UHFFFAOYSA-N 0.000 description 6
- 239000000243 solution Substances 0.000 description 6
- 230000000903 blocking effect Effects 0.000 description 5
- 238000005259 measurement Methods 0.000 description 5
- 210000001577 neostriatum Anatomy 0.000 description 5
- 238000002360 preparation method Methods 0.000 description 5
- 102000004506 Blood Proteins Human genes 0.000 description 4
- 108010017384 Blood Proteins Proteins 0.000 description 4
- 102000005915 GABA Receptors Human genes 0.000 description 4
- 108010005551 GABA Receptors Proteins 0.000 description 4
- TWRXJAOTZQYOKJ-UHFFFAOYSA-L Magnesium chloride Chemical compound [Mg+2].[Cl-].[Cl-] TWRXJAOTZQYOKJ-UHFFFAOYSA-L 0.000 description 4
- WCUXLLCKKVVCTQ-UHFFFAOYSA-M Potassium chloride Chemical compound [Cl-].[K+] WCUXLLCKKVVCTQ-UHFFFAOYSA-M 0.000 description 4
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 4
- 239000000284 extract Substances 0.000 description 4
- 229960003634 pimozide Drugs 0.000 description 4
- 230000001225 therapeutic effect Effects 0.000 description 4
- 241000282412 Homo Species 0.000 description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- 239000007983 Tris buffer Substances 0.000 description 3
- 238000006073 displacement reaction Methods 0.000 description 3
- 238000002474 experimental method Methods 0.000 description 3
- 239000002207 metabolite Substances 0.000 description 3
- 210000003296 saliva Anatomy 0.000 description 3
- 239000013049 sediment Substances 0.000 description 3
- 229950001675 spiperone Drugs 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- 229960002784 thioridazine Drugs 0.000 description 3
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 3
- UXVMQQNJUSDDNG-UHFFFAOYSA-L Calcium chloride Chemical compound [Cl-].[Cl-].[Ca+2] UXVMQQNJUSDDNG-UHFFFAOYSA-L 0.000 description 2
- 241000251730 Chondrichthyes Species 0.000 description 2
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 2
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 2
- 238000004458 analytical method Methods 0.000 description 2
- 239000005557 antagonist Substances 0.000 description 2
- 229960002507 benperidol Drugs 0.000 description 2
- 239000001110 calcium chloride Substances 0.000 description 2
- 229910001628 calcium chloride Inorganic materials 0.000 description 2
- 239000003153 chemical reaction reagent Substances 0.000 description 2
- 229960001076 chlorpromazine Drugs 0.000 description 2
- 238000004140 cleaning Methods 0.000 description 2
- 229960001184 clopenthixol Drugs 0.000 description 2
- 229960004170 clozapine Drugs 0.000 description 2
- 238000007796 conventional method Methods 0.000 description 2
- 239000012530 fluid Substances 0.000 description 2
- 229960002419 flupentixol Drugs 0.000 description 2
- 239000011521 glass Substances 0.000 description 2
- 239000003365 glass fiber Substances 0.000 description 2
- 229960000423 loxapine Drugs 0.000 description 2
- 229910001629 magnesium chloride Inorganic materials 0.000 description 2
- 239000012528 membrane Substances 0.000 description 2
- 239000001103 potassium chloride Substances 0.000 description 2
- 235000011164 potassium chloride Nutrition 0.000 description 2
- 230000035945 sensitivity Effects 0.000 description 2
- 238000000926 separation method Methods 0.000 description 2
- 239000011780 sodium chloride Substances 0.000 description 2
- DKGZKTPJOSAWFA-UHFFFAOYSA-N spiperone Chemical compound C1=CC(F)=CC=C1C(=O)CCCN1CCC2(C(NCN2C=2C=CC=CC=2)=O)CC1 DKGZKTPJOSAWFA-UHFFFAOYSA-N 0.000 description 2
- 239000006228 supernatant Substances 0.000 description 2
- 239000000725 suspension Substances 0.000 description 2
- 229960002324 trifluoperazine Drugs 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- WFPIAZLQTJBIFN-DVZOWYKESA-N zuclopenthixol Chemical compound C1CN(CCO)CCN1CC\C=C\1C2=CC(Cl)=CC=C2SC2=CC=CC=C2/1 WFPIAZLQTJBIFN-DVZOWYKESA-N 0.000 description 2
- ZZJYIKPMDIWRSN-TZBSWOFLSA-N (+)-butaclamol Chemical compound C12=CC=CC=C2CCC2=CC=CC3=C2[C@@H]1CN1CC[C@@](C(C)(C)C)(O)C[C@@H]13 ZZJYIKPMDIWRSN-TZBSWOFLSA-N 0.000 description 1
- SEPPVOUBHWNCAW-FNORWQNLSA-N (E)-4-oxonon-2-enal Chemical compound CCCCCC(=O)\C=C\C=O SEPPVOUBHWNCAW-FNORWQNLSA-N 0.000 description 1
- QHDXPJMOWRLLRV-UHFFFAOYSA-N 1-(4-fluorophenyl)butan-1-one Chemical compound CCCC(=O)C1=CC=C(F)C=C1 QHDXPJMOWRLLRV-UHFFFAOYSA-N 0.000 description 1
- OBVKBOLDEFIQDP-UHFFFAOYSA-N 2-methylsulfanyl-10h-phenothiazine Chemical compound C1=CC=C2NC3=CC(SC)=CC=C3SC2=C1 OBVKBOLDEFIQDP-UHFFFAOYSA-N 0.000 description 1
- 125000001494 2-propynyl group Chemical group [H]C#CC([H])([H])* 0.000 description 1
- OKDGPOCKHMGDQY-UHFFFAOYSA-N 3,4-dihydropyrrol-2-one Chemical compound O=C1CCC=N1 OKDGPOCKHMGDQY-UHFFFAOYSA-N 0.000 description 1
- 125000004195 4-methylpiperazin-1-yl group Chemical group [H]C([H])([H])N1C([H])([H])C([H])([H])N(*)C([H])([H])C1([H])[H] 0.000 description 1
- LLBZPESJRQGYMB-UHFFFAOYSA-N 4-one Natural products O1C(C(=O)CC)CC(C)C11C2(C)CCC(C3(C)C(C(C)(CO)C(OC4C(C(O)C(O)C(COC5C(C(O)C(O)CO5)OC5C(C(OC6C(C(O)C(O)C(CO)O6)O)C(O)C(CO)O5)OC5C(C(O)C(O)C(C)O5)O)O4)O)CC3)CC3)=C3C2(C)CC1 LLBZPESJRQGYMB-UHFFFAOYSA-N 0.000 description 1
- QOYHHIBFXOOADH-UHFFFAOYSA-N 8-[4,4-bis(4-fluorophenyl)butyl]-1-phenyl-1,3,8-triazaspiro[4.5]decan-4-one Chemical compound C1=CC(F)=CC=C1C(C=1C=CC(F)=CC=1)CCCN1CCC2(C(NCN2C=2C=CC=CC=2)=O)CC1 QOYHHIBFXOOADH-UHFFFAOYSA-N 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- 101100069818 Caenorhabditis elegans gur-3 gene Proteins 0.000 description 1
- 241000699662 Cricetomys gambianus Species 0.000 description 1
- PLDUPXSUYLZYBN-UHFFFAOYSA-N Fluphenazine Chemical compound C1CN(CCO)CCN1CCCN1C2=CC(C(F)(F)F)=CC=C2SC2=CC=CC=C21 PLDUPXSUYLZYBN-UHFFFAOYSA-N 0.000 description 1
- 239000004471 Glycine Substances 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- DPWPWRLQFGFJFI-UHFFFAOYSA-N Pargyline Chemical compound C#CCN(C)CC1=CC=CC=C1 DPWPWRLQFGFJFI-UHFFFAOYSA-N 0.000 description 1
- 241001494479 Pecora Species 0.000 description 1
- 241000283984 Rodentia Species 0.000 description 1
- 241000282887 Suidae Species 0.000 description 1
- VEXNFKCQMGMBBJ-UHFFFAOYSA-N [1-(dimethylamino)-2-[(dimethylamino)methyl]butan-2-yl] benzoate Chemical group CN(C)CC(CC)(CN(C)C)OC(=O)C1=CC=CC=C1 VEXNFKCQMGMBBJ-UHFFFAOYSA-N 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 239000000556 agonist Substances 0.000 description 1
- 230000003474 anti-emetic effect Effects 0.000 description 1
- 239000002111 antiemetic agent Substances 0.000 description 1
- 229940125683 antiemetic agent Drugs 0.000 description 1
- VMWNQDUVQKEIOC-CYBMUJFWSA-N apomorphine Chemical compound C([C@H]1N(C)CC2)C3=CC=C(O)C(O)=C3C3=C1C2=CC=C3 VMWNQDUVQKEIOC-CYBMUJFWSA-N 0.000 description 1
- 229960004046 apomorphine Drugs 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 210000005013 brain tissue Anatomy 0.000 description 1
- 238000009395 breeding Methods 0.000 description 1
- 230000001488 breeding effect Effects 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 238000001311 chemical methods and process Methods 0.000 description 1
- NJMYODHXAKYRHW-DVZOWYKESA-N cis-flupenthixol Chemical compound C1CN(CCO)CCN1CC\C=C\1C2=CC(C(F)(F)F)=CC=C2SC2=CC=CC=C2/1 NJMYODHXAKYRHW-DVZOWYKESA-N 0.000 description 1
- 238000004440 column chromatography Methods 0.000 description 1
- 238000004891 communication Methods 0.000 description 1
- 239000012141 concentrate Substances 0.000 description 1
- DIOQZVSQGTUSAI-UHFFFAOYSA-N decane Chemical compound CCCCCCCCCC DIOQZVSQGTUSAI-UHFFFAOYSA-N 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 239000003210 dopamine receptor blocking agent Substances 0.000 description 1
- 239000003136 dopamine receptor stimulating agent Substances 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 210000003608 fece Anatomy 0.000 description 1
- 238000000855 fermentation Methods 0.000 description 1
- 230000004151 fermentation Effects 0.000 description 1
- 239000000835 fiber Substances 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 125000006332 fluoro benzoyl group Chemical group 0.000 description 1
- 229960002690 fluphenazine Drugs 0.000 description 1
- 229960003532 fluspirilene Drugs 0.000 description 1
- 238000001030 gas--liquid chromatography Methods 0.000 description 1
- 230000035876 healing Effects 0.000 description 1
- 230000001771 impaired effect Effects 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 150000002497 iodine compounds Chemical class 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 239000010410 layer Substances 0.000 description 1
- 238000011866 long-term treatment Methods 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 229940126601 medicinal product Drugs 0.000 description 1
- 230000036651 mood Effects 0.000 description 1
- 230000010807 negative regulation of binding Effects 0.000 description 1
- 230000002182 neurohumoral effect Effects 0.000 description 1
- 239000012044 organic layer Substances 0.000 description 1
- 239000012074 organic phase Substances 0.000 description 1
- 239000003960 organic solvent Substances 0.000 description 1
- 229960001779 pargyline Drugs 0.000 description 1
- 229960000762 perphenazine Drugs 0.000 description 1
- 230000002085 persistent effect Effects 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 150000002990 phenothiazines Chemical class 0.000 description 1
- 125000004193 piperazinyl group Chemical group 0.000 description 1
- 230000036470 plasma concentration Effects 0.000 description 1
- 239000004033 plastic Substances 0.000 description 1
- 239000011148 porous material Substances 0.000 description 1
- 229960003598 promazine Drugs 0.000 description 1
- 239000004089 psychotropic agent Substances 0.000 description 1
- 210000002637 putamen Anatomy 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 230000000717 retained effect Effects 0.000 description 1
- 201000000980 schizophrenia Diseases 0.000 description 1
- 230000000698 schizophrenic effect Effects 0.000 description 1
- 239000012064 sodium phosphate buffer Substances 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 238000000527 sonication Methods 0.000 description 1
- 238000001179 sorption measurement Methods 0.000 description 1
- 230000009870 specific binding Effects 0.000 description 1
- 238000004611 spectroscopical analysis Methods 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 210000002182 synaptic membrane Anatomy 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/94—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving narcotics or drugs or pharmaceuticals, neurotransmitters or associated receptors
- G01N33/9406—Neurotransmitters
- G01N33/9413—Dopamine
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2500/00—Screening for compounds of potential therapeutic value
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Urology & Nephrology (AREA)
- Hematology (AREA)
- Biomedical Technology (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Medicinal Chemistry (AREA)
- Physics & Mathematics (AREA)
- Microbiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biotechnology (AREA)
- Food Science & Technology (AREA)
- Pharmacology & Pharmacy (AREA)
- Cell Biology (AREA)
- Analytical Chemistry (AREA)
- Biochemistry (AREA)
- General Health & Medical Sciences (AREA)
- General Physics & Mathematics (AREA)
- Pathology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US75998577A | 1977-01-17 | 1977-01-17 | |
| US82853777A | 1977-08-29 | 1977-08-29 | |
| US05/845,554 US4197288A (en) | 1977-01-17 | 1977-10-26 | Neuroleptic radioreceptor assay method and kit |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CH644456A5 true CH644456A5 (en) | 1984-07-31 |
Family
ID=27419530
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CH41778A CH644456A5 (en) | 1977-01-17 | 1978-01-16 | Method for determination of neuroleptics |
Country Status (7)
| Country | Link |
|---|---|
| JP (1) | JPS53112795A (OSRAM) |
| CH (1) | CH644456A5 (OSRAM) |
| DE (1) | DE2801679A1 (OSRAM) |
| FR (1) | FR2377634A1 (OSRAM) |
| GB (1) | GB1599133A (OSRAM) |
| NL (1) | NL7800517A (OSRAM) |
| SE (1) | SE448189B (OSRAM) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4248853A (en) * | 1978-09-08 | 1981-02-03 | Solomon Halbert Snyder | Assay method and kit |
-
1978
- 1978-01-16 SE SE7800462A patent/SE448189B/sv not_active IP Right Cessation
- 1978-01-16 DE DE19782801679 patent/DE2801679A1/de not_active Withdrawn
- 1978-01-16 GB GB1592/78A patent/GB1599133A/en not_active Expired
- 1978-01-16 NL NL7800517A patent/NL7800517A/xx not_active Application Discontinuation
- 1978-01-16 CH CH41778A patent/CH644456A5/de not_active IP Right Cessation
- 1978-01-16 FR FR7801052A patent/FR2377634A1/fr active Granted
- 1978-01-17 JP JP365278A patent/JPS53112795A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| NL7800517A (nl) | 1978-07-19 |
| DE2801679A1 (de) | 1978-07-20 |
| SE448189B (sv) | 1987-01-26 |
| SE7800462L (sv) | 1978-07-18 |
| GB1599133A (en) | 1981-09-30 |
| JPS53112795A (en) | 1978-10-02 |
| FR2377634B1 (OSRAM) | 1983-04-29 |
| FR2377634A1 (fr) | 1978-08-11 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DE69114403T2 (de) | Reagenz zur Proteinfällung. | |
| Golden et al. | Bupropion in depression: II. The role of metabolites in clinical outcome | |
| DE60120487T2 (de) | Verfahren zur detektion von vitamin d metaboliten | |
| DE2936307C2 (OSRAM) | ||
| DE2450523C3 (de) | Verfahren zum immunologischen Nachweis von Proteinen | |
| DE2705897A1 (de) | Mehrkomponenten-reagens zur bestimmung von cyclischem adenosin-3',5'- monophosphat und/oder cyclischem guanosin- 3',5'-monophosphat und seine verwendung | |
| DE2734118A1 (de) | Radioimmunologisches verfahren und einrichtung zur bestimmung von antigenen | |
| DE2953524A1 (de) | Biologisches messverfahren | |
| EP0257352B1 (de) | Verfahren und Testkit zur Bestimmung freier Wirkstoffe in biologischen Flüssigkeiten | |
| DE2560288C2 (de) | Probenhalter zur fluorometrischen Bestimmung von Substanzproben | |
| EP1339403B1 (de) | Repinotan-kit | |
| DE2333434C3 (de) | Verfahren zur Durchführung serologischer Untersuchungen nach dem Prinzip der Komplementbindungsreaktion und gebrauchsfertige Schnelltestpackung hierfür | |
| DE2419884A1 (de) | Verfahren und vorrichtung zur bestimmung von trijodthyronin | |
| US4520112A (en) | Assay method for organic calcium antagonist drugs and a kit for such an assay | |
| DE60108316T2 (de) | Medizinische Kit und Methode zur Bestimmung eines Arzneimittels | |
| CH627188A5 (OSRAM) | ||
| DE2902071A1 (de) | Verfahren und reagens zur bestimmung der konzentration von benzodiazepinen in einer koerperfluessigkeit | |
| DE3650691T2 (de) | Verfahren zum Messen von Freitestosteronen in biologischen Flüssigkeiten | |
| DE2820895A1 (de) | Verfahren zur bestimmung einer komponente in einer biologischen fluessigkeit | |
| CH685959A5 (de) | Diagnostische Testpackung zur Bestimmung von Proteinen. | |
| DE69811680T2 (de) | Stabile radioaktive medikamente | |
| DE3812610A1 (de) | Verfahren zur bestimmung der thyroxinbindekapazitaet und dazu geeignete standardloesung | |
| DE2801679A1 (de) | Verfahren zur bestimmung neuroleptischer arzneimittel | |
| Miles et al. | Determination of salivary digoxin with a dry strip immunometric assay | |
| DE2936277A1 (de) | Verfahren und ausruestung zur bestimmung der konzentration von beta -adrenergischen blockern und irgendwelchen aktiven stoffwechselprodukten davon in koerperfluessigkeiten |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PL | Patent ceased | ||
| PL | Patent ceased |